Outcomes and excess costs among patients with cardiovascular disease

Heart Lung and Circulation

Volumn 22, Issue 9, 2013, Pages 724-730

  Ademi, Zanfina ^a,b   Liew, Danny ^a   Zomer, Ella ^b   Gorelik, Alexandra ^a   Hollingsworth, Bruce ^c   Steg, Ph Gabriel ^d   Bhatt, Deepak L ^e   Reid, Christopher M ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d INSERM   (France)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular disease; Excess costs; Resource use

Indexed keywords

CARDIOVASCULAR AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PROCEDURE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE REGISTRY; DRUG COST; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE COST; HEART INFARCTION; HOSPITALIZATION COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REIMBURSEMENT;

CARDIOVASCULAR DISEASE; EXCESS COSTS; RESOURCE USE;

CARDIOVASCULAR DISEASES; COSTS AND COST ANALYSIS; FOLLOW-UP STUDIES; GENERAL PRACTITIONERS; REGISTRIES;

EID: 84884353705     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2013.02.002     Document Type: Article

References (25)

1. Bhatt D., Eagle K., Ohman M., Hirsch A., Goto S., Mahoney E., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients. at risk of or with atherothrombosis. JAMA 2010, 304:1350-1357.
2. Viles-Gonzalez J.F., Fuster V., Badimon J.J. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004, 25:1197-1207.
3. Access Economics. The shifting Burden of cardiovascular disease in Australia National Heart Foundation of Australia; 2005. Available from: http://www.heartfoundation.org.au/SiteCollectionDocuments/cvd%20shifting%20burden.pdf.
4. Rosamond W., Flegal K., Furie K., Go A., Greenlund K., Haase N., et al. Heart disease and stroke statistics: 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-e146.
5. Canadian Heart Health Strategy and Action Plan Steering Committe. Building a Heart Healthy Canada. Canadian Heart Health Strategy Action Plan, 2009.
6. Werblow A., Felder S., Zweifel P. Population ageing and health care expenditure: a school of 'red herrings'?. Health Econ 2007, 16:1109-1126.
7. Lye M. What makes the elderly person an expensive patient? The role of cardiovascular disease, comorbidity and treatment. Cardiovasc Drugs Ther 2001, 15:355-358.
8. Mahoney E.M., Wang K., Cohen D.J., Hirsch A.T., Albert M.J., Eagle K., et al. One-year costs in patients with history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 2008, 1:38-45.
9. Mahoney E., Wang K., Keo H., Duval S., Smolderen K., Cohen D., et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators, Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes 2010, 3:642-651.
10. Smolderen K.G., Bell A., Lei Y., Cohen E.A., Steg P.G., Bhatt D.L., et al. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Can J Cardiol 2010, 26:297-305.
11. Ademi Z., Liew D., Hollingsworth B., Wolfe R., Steg G.P., Bhatt D.L., et al. The economic implications of treating atherothrombotic disease in Australia, from the government perspective. Clin Ther 2010, 32:119-132.
12. Steg P.G., Bhatt D.L., Wilson P.W.F., D'Agostino R., Ohman E.M., Rother J., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007, 297:1197-1206.
13. Pharmaceutical Benefits Schedule Item Reports. Period June 2011 to May 2012. Available from: https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml%20Accessed:%2002/10/2012.
14. Ademi Z., Liew D., Chew D., Conner G., Shiel L., Nelson M., et al. Drug treatment and cost of cardiovascular disease in Australia. Cardiovas Ther 2009, 27:164-172.
15. Schedule of Pharmaceutical Benefits for approved pharmacists and medical practitioners 2011. Available from: http://www.pbs.gov.au/browse/medicine-listing%20Accessed%3A%2002/10/2011.
16. Medicare Benefits Schedule Book. Australian Government Department of Health and Ageing. July 2010. Available through: (accessed: 10.06.2011). http://www.health.gov.au/mbsonline.
17. Public Sector Estimated Cost Weights Round 12 AR-DRG v5.1 (Excel 276 KB). Available from (accessed: 03.06.2012). http://www.health.gov.au/internet/main/publishing.nsf/Content/Round_12-cost-reports.
18. Health expenditure Australia 2008-09. Available through: (accessed: 05.05.2012). http://www.aihw.gov.au/publication-detail/%3Fid=6442472450%26tab=2.
19. Duckett S.J. The Australian health care system, South Melbourne 2007, Oxford University Press, Vic. 3rd ed.
20. Duckett S.J. Casemix funding for acute hospital inpatient services in Australia. MJA 1998, 169:S17-S21.
21. Migliaccio-Walle K., Caro J.J., Ishak K.J., O'Brien J.A. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharmacoeconomics 2005, 23:733-742.
22. Levy E., Gabriel S., Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003, 21:651-659.
23. Reid C.M., Ademi Z., Nelson M.R., Connor G., Chew D.P., Shiel L., et al. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust 2012 Feb 20, 196(3):193-197.
24. Ademi Z., Liew D., Hollingsworth B., Steg P.G., Bhatt D.L., Reid C.M. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry. Am J Cardiovasc Drugs 2010, 10:85-94.
25. Garson A. The US healthcare system 2010: problems, principles, and potential solutions. Circulation 2000, 101:2015-2016.